NHI.no
Annonse
Informasjon

Psoriasisartritt

Psoriasisartritt er en type leddgikt som ses hos rundt femten prosent av de som har hudsykdommen psoriasis. Tidlig påvisning og behandling av leddsykdom ved psoriasis er viktig for prognosen og kan hos en del forhindre varig skade i ledd.

Psoriasisartritt gir symptomer som hevelse, ømhet og nedsatt bevegelse i de leddene som er angrepet.

Sist oppdatert:

23. des. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Psoriasisartritt . Referanselisten for dette dokumentet vises nedenfor

  1. Madland TM, Hoff M, Thomsen R, Michelsen B. Psoriasisartritt (PsA). Nasjonal veileder i revmatologi. Norsk reumatologisk forening. Publisert 19.06.2020, siden besøkt 01.10.2020 norskrevmatologi.no
  2. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1-19. PubMed
  3. Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009 Feb;36(2):361-7. PubMed
  4. Scott IC, Whittle R, Bailey J, et al. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg Health Eur 2022. pmid:36246147 PubMed
  5. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009; 11: 214. pmid:19232079 PubMed
  6. McLeod BD. Site of psoriasis (scalp or intergluteal/perianal), >or=3 affected sites, and nail dystrophy predicted psoriatic arthritis in incident psoriasis. Evid Based Med. 2009 Dec;14(6):185. PMID: 19949187. PubMed
  7. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73. pmid:16871531 PubMed
  8. D'Angelo S, Mennillo GA, Cutro MS, et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol 2009; 36: 368-70. pmid:19208566 PubMed
  9. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity?. Ann Rheum Dis 2005; 64: 188. pmid:15271771 PubMed
  10. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123. pmid:17216680 PubMed
  11. Villani AP,Rouzaud M,Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2015. PMID: 26054432 PubMed
  12. Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register, 2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):668-73. PubMed
  13. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006; 65: 478. pmid:16126794 PubMed
  14. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factorαtherapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382. pmid:21279995 PubMed
  15. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD000212. DOI: 10.1002/14651858.CD000212 DOI
  16. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. PMID: 32434812 PubMed
  17. Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriathic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009-e:pub.
  18. Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD012722. DOI: 10.1002/14651858.CD012722.pub2. DOI
  19. Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136):2285-2294. Epub 2018 Jun 1. PMID: 29893227.
  20. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33: 1422. pmid:16724372 PubMed
  21. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35: 883. pmid:18381787 PubMed
  22. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthrtis Rheum 2005 Oct;52(10):3279-89. PubMed
  23. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005 Aug;64(8):1150-7. PubMed
  24. Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014 Oct;34(10):1345-60. doi: 10.1007/s00296-014-3006-2 DOI
  25. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2013 Oct 16.
  26. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73: 233-7. pmid:23942869 PubMed
  27. Merola JF, Landawé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2022. doi:10.1016/S0140-6736(22)02303-0 DOI
  28. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2022. doi:10.1016/S0140-6736(22)02302-9 DOI
  29. McInnes IB1, Mease PJ2, Kirkham B3, Kavanaugh A4, Ritchlin CT5, Rahman P6, van der Heijde D7, Landewé R8, Conaghan PG9, Gottlieb AB10, Richards H11, Pricop L12, Ligozio G12, Patekar M13, Mpofu S11; FUTURE 2 Study Group.. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-46. doi:26135703
  30. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015; 373: 1329-39. doi:26422723
  31. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group . Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.. Lancet 2013; 382: 780-9. doi:23769296
  32. Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Published January 2023. Doi: 10.1016/S2665-9913(22)00329-0 DOI
  33. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5. PubMed
  34. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4. PubMed
  35. Charlton R, Green A, Shaddick G, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis. 2017. PMID: 29092855 PubMed
  36. Guldberg-Møller J, Cordtz RL, Kristensen LE, Dreyer L. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. epub 215313. pmid:31300461 PubMed
  37. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74: 326-32. pmid:25351522 PubMed
  38. Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2019. pmid:31672774 PubMed
Annonse
Annonse